Warning letter
Laclede Inc: warning letter of Feb 14, 2013
FDA warning letter 329042 · Los Angeles District Office
Key facts
| Reference number | 329042 |
|---|---|
| Company | Laclede Inc |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated/Misbranded |
| Issue date | Feb 14, 2013 |
| Posted date | Feb 14, 2013 |
| Issuing office | Los Angeles District Office |
| Product type | Drugs |
| CFR sections cited | 201.66, 201.66(b)(2), 211.84(d)(2), 211.165(a), 211.166(a) |
| Inspection city | Rancho Dominguez |
| Inspection ZIP | 90220 |
| Inspection start date | Jun 19, 2012 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: